Symbiox Investment & Trading Company Ltd

Meeting Details

• Board meeting on 26 August 2026 at 2:00 PM at Registered Office.

Key Agenda Items

• Consider and approve Director Report, MD&A, and Corporate Governance Report for FY 2025-26.
• Consider and fix dates for closure of Register of Members and Transfer Books.
• Consider and fix day, date, time, venue, and calendar for the AGM.
• Appoint Scrutinizer for e-voting and polling at the AGM.
• Take note on status of statutory registers under Companies Act 2013.
• Consider and approve Notice of 47th AGM.

Other Notes

• Trading window closure period not specified in the filing.

Financial results and audit

• Unaudited financial results for the quarter ended 30 June 2026 approved by the Board.
• Auditor's Limited Review Report adopted for the quarter ended 30 June 2026.
• Audit report notes: no qualifications in the auditor's report.
• No other matters transacted at the meeting.

Demat/Remat status

• Demat/remat details processed and furnished to depositories and stock exchanges.
• Dematerialised securities mutilated and cancelled after verification; depository named as registered owner.
• Dematerialised securities listed on the exchanges where listed.
• Processing done via RTA (Registrar and Transfer Agent).

Financial performance

• 📊 Revenue from operations fell to ₹8.60 lakh in Q4 FY26 from ₹124.50 lakh QoQ.
• 📊 FY26 revenue from operations was ₹276.36 lakh, versus ₹160.29 lakh in FY25.
• 📊 Total income was ₹8.64 lakh in Q4 FY26 and ₹276.79 lakh in FY26.
• 📊 Q4 FY26 profit before tax was ₹1.65 lakh, versus loss of ₹40.46 lakh YoY.
• 📊 FY26 profit before tax was ₹25.93 lakh, versus ₹20.58 lakh in FY25.
• 📊 FY26 profit after tax was ₹15.23 lakh, versus ₹19.19 lakh in FY25.
• 📊 Q4 FY26 profit after tax was ₹1.23 lakh, versus loss of ₹29.94 lakh YoY.
• 📊 Basic and diluted EPS were ₹0.004 in Q4 FY26 and ₹0.049 in FY25.
• 📊 FY26 basic and diluted EPS were ₹0.049, versus ₹0.061 in FY25.

Cost trends

• 📊 FY26 total expenses were ₹250.86 lakh, versus ₹139.94 lakh in FY25.
• 📊 Purchases of stock-in-trade were ₹332.12 lakh in FY26, versus ₹33.67 lakh in FY25.
• 📊 Inventory changes were a ₹66.25 lakh release in FY26, versus ₹120.68 lakh build in FY25.
• 📊 Employee benefits expense rose to ₹20.47 lakh in FY26 from ₹15.34 lakh.
• 📊 Other expenses increased to ₹23.79 lakh in FY26 from ₹19.26 lakh.
• 📊 Finance costs remained nil across the reported periods.

Financial position

• 📊 Total assets were ₹3,197.60 lakh at 31 March 2026, broadly flat versus ₹3,196.59 lakh.
• 📊 Current investments rose to ₹1,532.72 lakh from ₹1,271.43 lakh.
• 📊 Current loans fell to ₹1,432.41 lakh from ₹1,645.68 lakh.
• 📊 Inventories declined to ₹63.39 lakh from ₹129.64 lakh.
• 📊 Cash and cash equivalents increased to ₹117.18 lakh from ₹105.88 lakh.
• 📊 Equity stood at ₹3,187.63 lakh, with share capital of ₹3,128.73 lakh.
• 📊 Operating cash flow was ₹272.59 lakh in FY26, versus ₹357.36 lakh in FY25.
• 📊 Investing cash flow was negative ₹261.29 lakh in FY26, versus negative ₹283.58 lakh in FY25.

Board decisions

• 📍 Board approved audited standalone financial results for quarter and year ended 31 March 2026.
• 📍 Board approved re-appointment of Akhil Agarwal as secretarial auditor for FY27.
• 📍 Board approved re-appointment of Shikha Singhal & Associates as internal auditor for FY27.
• 📍 Statutory auditors issued an unmodified opinion on the audited financial results.

Audit opinion

• 🗒️ Auditors reported the standalone annual financial results give a true and fair view.
• 🗒️ The report states no qualification in the audit report issued by the auditor.

Business model

• 🗒️ Symbiox Investment & Trading Co Ltd operates as an investment and trading company.
• 🗒️ Reported assets include current investments and current loans, indicating treasury-style operations.

Financial Performance 📊

• Approved unaudited standalone financial results for quarter ended 31 December 2025.
• Total income for the quarter was Rs. 8.64 lakh.
• Profit before tax was Rs. 1.66 lakh; profit after tax Rs. 1.23 lakh.
• Basic and diluted earnings per share were Rs. 0.004 for the quarter.
• No exceptional items or discontinued operations reported.

Audit and Compliance ⚠️

• Adopted auditor’s limited review report for the quarter ended 31 December 2025 with no material misstatements.

Capital Structure

• Paid-up equity share capital remained Rs. 31.29 crore with Rs. 10 face value per share.